This approach not only increases the sensitivity of non-small cell lung cancer (NSCLC) cells to ATR inhibitors but can also be used to treat SLFN11-low tumors resistant to platinum-based and PARP inhibitors while inhibiting the progression of small cell lung cancer (SCLC) by modulating tumor-associated macrophages (TAMs) and the epithelial–mesenchymal transition (EMT) (158, 159). Here, SLFN11 is linked to non-small cell lung carcinoma.